Loading
TP
TFF Pharmaceuticals, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by ROCAMBOLI STEPHEN, was filed 15 Aug 2023.
TFF Pharmaceuticals, Inc.: what insiders have been doing
TFF Pharmaceuticals, Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). TFF Pharmaceuticals, Inc. has had no insider filing for more than a year; the last one goes back to 8 July 2024.
Our records for TFF Pharmaceuticals, Inc. go back to 2019, with 40 purchases and 30 sales on the open market in total.
Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
101
Thresholds
n/a
Buy Volume
€5M
40 ops. · all time
Sell Volume
€29M
30 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2023FY ended December 2023 · cache
Income statement
RevenueUS$631.9k
Net income-US$18.3M-2894.7% margin
Last declaration on 8 July 2024
Declarations101 total
27,480 shares0Common StockSEC:0001213900-24-059878:0
1,583 shares0Common StockSEC:0001213900-24-059871:0
1,583 shares0Common StockSEC:0001213900-24-059877:0
10,184 shares0Common StockSEC:0001213900-24-059874:0
3,165 shares0Common StockSEC:0001213900-24-059876:0
3,165 shares0Common StockSEC:0001213900-24-059875:0
3,165 shares0Common StockSEC:0001213900-24-059872:0
10,184 shares0Common StockSEC:0001213900-24-059873:0
1,000 shares@ US$0.39160.4% of flowCommon StockSEC:0000899243-23-018209:1
215,000 shares@ US$0.4374100.0% of flowCommon Stock, par value $0.001 per share (the "Common Stock"SEC:0000899243-23-018209:0
20,000 shares@ US$0.2516.7% of flowCommon StockSEC:0001213900-23-067445:0
Canonical exit: 13 Nov 2023 (T+90)
20,000 shares@ US$0.25100.0% of flowCommon StockSEC:0001213900-23-067444:0
Canonical exit: 13 Nov 2023 (T+90)
20,000 shares@ US$0.2518.3% of flowCommon StockSEC:0001213900-23-067441:0
Canonical exit: 13 Nov 2023 (T+90)
120,000 shares@ US$0.2570.3% of flowCommon StockSEC:0001213900-23-067440:0
Canonical exit: 13 Nov 2023 (T+90)
40,000 shares@ US$0.25100.0% of flowCommon StockSEC:0001213900-23-067442:0
Canonical exit: 13 Nov 2023 (T+90)
600,000 shares@ US$0.2541.0% of flowCommon StockSEC:0001213900-23-067446:0
Canonical exit: 13 Nov 2023 (T+90)
12,000 shares@ US$0.788135.7% of flowCommon StockSEC:0001213900-23-019387:0
Canonical exit: 8 Jun 2023 (T+90)
150,000 shares@ US$0.878937.1% of flowCommon StockSEC:0001213900-23-019384:0
Canonical exit: 8 Jun 2023 (T+90)
13,000 shares@ US$0.802535.9% of flowCommon StockSEC:0001213900-23-019577:0
Canonical exit: 8 Jun 2023 (T+90)
15,000 shares@ US$0.8229.7% of flowCommon StockSEC:0001213900-23-019383:0
Canonical exit: 8 Jun 2023 (T+90)
50,000 shares@ US$1.0614.8% of flowCommon StockSEC:0001213900-22-080672:0
Canonical exit: 15 Mar 2023 (T+90)
43,470 shares@ US$1.151.4% of flowCommon StockSEC:0001213900-22-074720:0
Canonical exit: 20 Feb 2023 (T+90)
40,255 shares@ US$4.2919.1% of flowCommon StockSEC:0001213900-22-060782:1
40,255 shares@ US$2.5092.7% of flowCommon StockSEC:0001213900-22-060782:0
4,615 shares@ US$5.506.3% of flowCommon StockSEC:0001213900-22-028628:1
Canonical exit: 18 Aug 2022 (T+90)
25 of 101 declarations
About TFF Pharmaceuticals, Inc.
TFF Pharmaceuticals, Inc. is a United States-based clinical-stage biopharmaceutical company whose business has historically centered on its proprietary Thin Film Freezing (TFF) platform. The company was formed as a Delaware corporation on January 24, 2018, using intellectual property and other assets contributed from Lung Therapeutics. Its core thesis has been to create improved drug formulations for poorly soluble compounds, with particular emphasis on inhaled and dry-powder delivery formats that may enhance solubility, bioavailability, and pharmacokinetic performance. The company’s operating footprint has been associated over time with Austin and Fort Worth, Texas, and later Foxboro, Massachusetts in the context of its wind-down and planned deregistration. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1733413/000121390024027185/ea0201339-10k_tffpharma.htm?utm_source=openai))
From a business-model standpoint, TFFP has not been a commercial pharmaceutical company but rather a platform-driven development story. Its main programs have included dry-powder inhalation formulations such as TFF VORI (voriconazole) and TFF TAC (tacrolimus), both aimed at respiratory or transplant-related applications. The company has also extended the platform into broader respiratory research, including a collaboration with the National Institute of Environmental Health Sciences to develop dry-powder hyaluronan formulations for respiratory diseases. That collaboration underscores management’s intent to position TFF as a formulation-enabling technology with potential for licensing and strategic partnerships, rather than relying solely on internal product commercialization. ([nasdaq.com](https://www.nasdaq.com/press-release/tff-pharmaceuticals-enters-into-crada-with-the-national-institute-of-environmental?utm_source=openai))
Read moreShow less
TFF Pharmaceuticals listed on the Nasdaq Capital Market in October 2019 under the ticker TFFP. Over time, the company issued clinical updates, reported preclinical data supporting its aerosol delivery approach, and completed equity financings to support operations. In 2024 it completed additional capital raises, consistent with the cash-intensive nature of early-stage biotech development. However, the most important recent corporate event came in February 2025, when TFF announced that it had notified Nasdaq of its intent to voluntarily delist and stated that this action was tied to a planned liquidation and dissolution of the company, with no alternative listing venue arranged. For investors, this means TFFP should no longer be viewed as a standard growth biotech listed on a major US exchange, but rather as a company in terminal restructuring phase. ([nasdaq.com](https://www.nasdaq.com/press-release/tff-pharmaceuticals-announces-delisting-nasdaq-and-potential-sec-deregistration-2025?utm_source=openai))
In competitive terms, TFFP occupied a specialized niche in inhaled dry-powder formulation science. Its competitive advantage was the TFF technology itself, which the company believed could create differentiated drug-delivery profiles. At the same time, the company faced the typical constraints of clinical-stage biotech: no approved products, no meaningful commercial revenue base, and ongoing dependence on external capital and partnership execution. The recent corporate narrative is therefore dominated less by pipeline expansion than by financing, strategic advisory work on partnerships and licensing, and ultimately the delisting and wind-down announcement. For market participants, the key takeaway is that TFF Pharmaceuticals was an innovation-led biotech issuer on the Nasdaq in the United States, but one that moved into liquidation mode in 2025. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1733413/000121390024027185/ea0201339-10k_tffpharma.htm?utm_source=openai))
